APGE Apogee Therapeutics, Inc. Common Stock

BTIG has reiterated its Buy rating on Apogee Therapeutics Inc (NASDAQ:APGE) with a $115.00 price target, viewing recent developments as a "positive clearing event" for Apogee’s APG279 and APG777 candidates. The firm highlighted strong results from Apogee’s APEX Part A trial, with further efficacy expected from Part B results in Q2 2026. Initial head-to-head results against Dupixent are anticipated in H2 2026, with potential for JAK-like efficacy from Apogee's treatments.

Jane Henderson, Chief Financial Officer of Apogee Therapeutics, sold 1,500 shares of the company's common stock for $120,000 on December 19, 2025. This transaction, executed under a Rule 10b5-1 trading plan, leaves her with 193,371 directly owned shares. The sale occurred while the stock was near its 52-week high, with InvestingPro suggesting it might be overvalued despite a 64.8% surge over the past year.

Apogee Therapeutics Inc. (APGE) recently achieved an all-time high stock price of $78.19, reflecting a 64.5% appreciation over the last year. This surge is backed by strong analyst confidence, with a "Strong Buy" consensus and a high price target of $116, fueled by promising Phase 1 clinical trial results for its experimental antibody APG333 and favorable coverage from multiple investment firms. Despite strong liquidity, InvestingPro notes the stock is trading above its Fair Value, and profitability is not anticipated this year.

Apogee Therapeutics Inc. has reached an all-time high stock price of $78.19 USD, reflecting a 64.5% appreciation over the last year. Despite being considered overbought and not anticipated to be profitable this year, analysts maintain a "Strong Buy" consensus with a high price target of $116. The company recently announced positive interim Phase 1 results for its experimental antibody APG333 and has received favorable coverage from multiple investment firms.

Apogee Therapeutics Inc. (APGE) recently reached an all-time high of $78.19, marking a 64.5% appreciation over the last year, driven by strong investor confidence and a "Strong Buy" analyst consensus with a high price target of $116. While the company boasts a robust market cap of $5.22 billion and excellent liquidity, InvestingPro indicates the stock is currently trading above its Fair Value. The positive momentum is further supported by promising interim results for its experimental antibody APG333 and favorable coverage from multiple investment firms.

Stephens upgraded Apogee Therapeutics (NASDAQ:APGE) to a "strong-buy" rating, contributing to an overall bullish analyst consensus with an average price target of $98.50. The stock is trading near its 52-week high, and despite recent insider stock sales, institutional investors have increased their holdings. Apogee Therapeutics focuses on developing biologics for inflammatory and immunology indications like atopic dermatitis, asthma, and COPD.